Kyverna Therapeutics, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2018-01-01
- Employees
- 96
- Market Cap
- $347.3M
- Website
- http://www.kyvernatx.com
KYSA-8: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD-19 CAR T) Therapy, in Subject With Treatment Refractory Stiff Person Syndrome
- Conditions
- Stiff-Person SyndromeSPS
- Interventions
- Biological: Standard lymphodepletion regimen
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Kyverna Therapeutics
- Target Recruit Count
- 25
- Registration Number
- NCT06588491
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
🇺🇸Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis
- Conditions
- Systemic Sclerosis - Diffuse CutaneousSystemic SclerosisSystemic Sclerosis - 2013 ACR/EULAR Classification Criteria
- Interventions
- Biological: KYV-101Drug: Standard lymphodepletion regimen
- First Posted Date
- 2024-05-06
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Kyverna Therapeutics
- Target Recruit Count
- 21
- Registration Number
- NCT06400303
- Locations
- 🇺🇸
Stanford University Medical Center, Palo Alto, California, United States
🇺🇸Northwell Health, Great Neck, New York, United States
KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis
- Conditions
- Multiple Sclerosis, Primary ProgressiveMultiple Sclerosis, Secondary ProgressiveMultiple SclerosisMS
- Interventions
- First Posted Date
- 2024-04-25
- Last Posted Date
- 2025-01-13
- Lead Sponsor
- Kyverna Therapeutics
- Target Recruit Count
- 120
- Registration Number
- NCT06384976
- Locations
- 🇺🇸
Stanford University Medical Center, Palo Alto, California, United States
KYSA-3: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis
- Conditions
- Lupus NephritisLupus Nephritis - WHO Class IVLupus Nephritis - WHO Class III
- Interventions
- Biological: KYV-101 anti-CD19 CAR-T cell therapyDrug: Standard lymphodepletion regimen
- First Posted Date
- 2024-04-02
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Kyverna Therapeutics
- Target Recruit Count
- 32
- Registration Number
- NCT06342960
- Locations
- 🇩🇪
Fraunhofer-Institut für Translationale Medizin und Pharmakologie ITMP, Frankfurt, Germany
🇩🇪Charite- Universitätsklinikum Berlin, Berlin, Germany
🇩🇪Universitätsklinikum Carl Gustav Carus Dresden, Dresden, Germany
A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Subjects With Refractory Generalized Myasthenia Gravis
- Conditions
- Myasthenia GravisGeneralized Myasthenia Gravis
- Interventions
- Drug: Standard lymphodepletion regimen
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Kyverna Therapeutics
- Target Recruit Count
- 20
- Registration Number
- NCT06193889
- Locations
- 🇺🇸
University of California, Irvine, Orange, California, United States
🇺🇸Stanford University Medical Center, Palo Alto, California, United States
🇺🇸University of Miami, Miami, Florida, United States
KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis
- Conditions
- Lupus NephritisLupus Nephritis - World Health Organization (WHO) Class IIILupus Nephritis - WHO Class IV
- Interventions
- Biological: KYV-101 anti-CD19 CAR-T cell therapyDrug: Standard lymphodepletion regimen
- First Posted Date
- 2023-07-10
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Kyverna Therapeutics
- Target Recruit Count
- 32
- Registration Number
- NCT05938725
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Ohio State University Wexner Medical Center, Columbus, Ohio, United States
🇺🇸University of Colorado, Denver, Colorado, United States